Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPhysiomics Share News (PYC)

Share Price Information for Physiomics (PYC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.30
Bid: 1.20
Ask: 1.40
Change: 0.00 (0.00%)
Spread: 0.20 (16.667%)
Open: 1.30
High: 1.30
Low: 1.30
Prev. Close: 1.30
PYC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: Fletcher King optimistic; Angle in Astra deal

Fri, 03rd May 2024 10:52

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Friday.

----------

AIM - WINNERS

----------

Fletcher King PLC, up 26% at 44.00 pence, 12-month range 31.00p-49.00p. It reports a "strong second half business performance", a turnaround from the more "cautionary business outlook" it gave back in December. Revenue for the year ended April 30 "is now expected to be materially higher than management expectations". Pretax profit is expected to be between two and three times higher than the GBP192,000 it reported for the prior year.

----------

Angle PLC, up 11% at 15.20 pence, 12-month range 9.07p-37.40p. The firm strikes a deal with AstraZeneca to develop a "Parsortix-based androgen receptor" detection assay to be used in prostate cancer studies. Medical diagnostics provider Angle says the deal is worth GBP550,000.

----------

AIM - LOSERS

----------

Physiomics PLC, down 16% at 1.26p, 12-month range 0.90p-3.29p. The data science company, focused on new therapeutics and personalised medicine solutions, warns several large contracts have taken longer than expected to be signed. It predicts total income for the year to June 30 will decline to a range of GBP600,000-GBP650,000 as a result. It adds: "The company is in the final stages of negotiation for two projects (one with an existing client and one with a potential new client), the total value of which is expected to be, in aggregate, approximately GBP350,000. Whilst the board anticipates that the contracts for these two projects will be signed in FY24, the majority of the revenue is now expected be recognised in the company's next financial year ending 30 June 2025, and accordingly the board's expectations for FY25 revenues have been correspondingly increased. "

----------

By Eric Cunha, Alliance News news editor

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
7 Mar 2022 14:55

IN BRIEF: Physiomics confident for full-year, in talks for new client

Physiomics PLC - oncology consultancy based in Oxford, England - Pretax loss widens to GBP170,000 in six months that ended December 31 from GBP132,000 a year before, as revenue stays flat at GBP366,000 from GBP363,000. Notes has contracted revenue of GBP460,000 for the second of its financial year, which ends June 30, and is "well positioned to meet market expectations". Physiomics says it has a strong pipeline of products in advanced discussion, including with a potential new "large pharmaceutical client".

Read more
2 Mar 2022 20:28

TRADING UPDATES: MediaZest virus hit; SpaceandPeople Network Rail deal

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

Read more
23 Feb 2022 14:48

IN BRIEF: Physiomics chair steps down after 15 years; CEO adds role

Physiomics PLC - oncology consultancy based in Oxford, England - Non-Executive Chair Paul Harper steps down from board immediately, having served on the board since 2004 and as chair since 2007. Chief Executive Officer Jim Millen will take on the additional role of executive chair. Physiomics also will recruit one independent non-executive director "as soon as possible".

Read more
21 Feb 2022 14:31

IN BRIEF: Physiomics shares up on continued DoseMeRx collaboration

Physiomics PLC - oncology consultancy based in Oxford - Confirms it will continue to collaborate with DoseMeRx, after Tabula Rasa Healthcare Inc announces it will sell DoseMeRx. The collaboration will explore further commercial opportunities in cancer field. Over 2021, Physiomics' personalised dosing application for docetaxel prostate cancer treatment was integrated into DoseMeRx platform, and was met with positive feedback.

Read more
22 Dec 2021 21:22

TRADING UPDATES: Mercia buys more Intechnica; Anexo scores VW win

TRADING UPDATES: Mercia buys more Intechnica; Anexo scores VW win

Read more
13 Dec 2021 20:22

IN BRIEF: Physiomics signs new deals with Merck worth GBP300,000

IN BRIEF: Physiomics signs new deals with Merck worth GBP300,000

Read more
13 Dec 2021 13:31

Physiomics signs £0.3m of new agreements with Merck

(Sharecast News) - Oncology consulting company Physiomics announced on Monday that it has signed new agreements with its existing client Merck with a total value of £0.3m.

Read more
16 Nov 2021 16:09

UK shareholder meetings calendar - next 7 days

UK shareholder meetings calendar - next 7 days

Read more
22 Oct 2021 13:06

IN BRIEF: Physiomics pens further deals with Merck KGaA

IN BRIEF: Physiomics pens further deals with Merck KGaA

Read more
22 Oct 2021 09:13

Physiomics awarded further contracts with Merck

(Sharecast News) - Oncology drug development consultancy Physiomics said on Friday that it had been awarded two further contracts by existing client Merck.

Read more
30 Sep 2021 15:45

EARNINGS UPDATES: Northbridge "delighted"; Echo Energy loss narrows

EARNINGS UPDATES: Northbridge "delighted"; Echo Energy loss narrows

Read more
23 Sep 2021 15:59

UK earnings, trading statements calendar - next 7 days

UK earnings, trading statements calendar - next 7 days

Read more
16 Sep 2021 20:36

IN BRIEF: Physiomics recruits first patient for Partner study

IN BRIEF: Physiomics recruits first patient for Partner study

Read more
21 May 2021 17:51

TRADING UPDATES: Arkle spots gold; SDCL seals USD177 million buy

TRADING UPDATES: Arkle spots gold; SDCL seals USD177 million buy

Read more
21 May 2021 11:48

AIM WINNERS & LOSERS: Arkle finds gold; Staffline raises cash

AIM WINNERS & LOSERS: Arkle finds gold; Staffline raises cash

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.